Absci (NASDAQ:ABSI) used a presentation at the Leerink Partners Global Healthcare Conference to outline how the company is applying its internal AI-driven drug design platform to generate ...

For the primary endpoint, patients treated with povetacicept achieved a 52.0% reduction from baseline in proteinuria as measured by 24-hour urine protein to creatinine ratio (UPCR) and achieved a ...